Summit Therapeutics (NASDAQ: SMMT) is a notable publicly traded company with a market cap exceeding $10 billion, yet it has generated no revenue. Despite a recent decline in stock value, which peaked above $27 billion earlier this year, investor interest remains high due to its promising asset, ivonescimab, which is not yet approved. This optimism suggests potential for substantial future growth, with possibilities for the stock to double or triple. Investors are betting on Summit’s future impact in the healthcare sector.
